Pfizer Venture Investments

Type

CVC

Status

Active

Location

New York, United States

Total investments

156

Average round size

45M

Portfolio companies

100

Rounds per year

7.80

Lead investments

27

Follow on index

0.36

Exits

39

Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

Pfizer Venture Investments appeared to be the VC, which was created in 2004. The leading representative office of defined VC is situated in the New York. The fund was located in North America if to be more exact in United States. Pfizer Venture Investments seemed to be an CVC arrangement as part of the organization.

The increased amount of exits for fund were in 2016. Deals in the range of 10 - 50 millions dollars are the general things for fund. Considering the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. The top activity for fund was in 2016. Despite it in 2019 the fund had an activity. The fund is constantly included in 2-6 investment rounds annually.

Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Merus, Epic Sciences, TetraLogic Pharmaceuticals. The fund has no exact preference in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the most successful fund investment fields, there are Therapeutics, Pharmaceutical.

The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Pfizer Venture Investments, startups are often financed by Roche Venture Fund, Atlas Venture, Three Arch Partners. The meaningful sponsors for the fund in investment in the same round are Lundbeckfonden Ventures, Sofinnova Partners, OrbiMed. In the next rounds fund is usually obtained by New Enterprise Associates, SR One, Rock Springs Capital.

We also calculated 8 valuable employees in our database.

Show more

Investor highlights

Industry focus
Biotech/Life SciencesMedtech
Stage focus
Generalist
Geo focus
United States
Check size
Up to 20M

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
156
Lead investments
27
Exits
39
Rounds per year
7.80
Follow on index
0.36
Investments by industry
  • Biotechnology (136)
  • Health Care (106)
  • Therapeutics (81)
  • Medical (43)
  • Pharmaceutical (34)
  • Show 28 more
Investments by region
  • United States (120)
  • United Kingdom (18)
  • Switzerland (6)
  • France (2)
  • Netherlands (3)
  • Show 4 more
Peak activity year
2022
Number of Minotaurs
3

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
11
Avg. valuation at time of investment
40M
Group Appearance index
0.94
Avg. company exit year
8
Avg. multiplicator
1.94
Strategy success index
0.80

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Grey Wolf Therapeutics 23 May 2024 Biotechnology, Health Care, Therapeutics Early Stage Venture 50M England, Oxford, United Kingdom
Mozart Therapeutics 07 Jun 2023 Biotechnology Early Stage Venture 25M
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.